Articles tagged with Metastasis
Researchers uncovered unique genomic instability in pancreatic cancer, which drives tumor adaptation and spread. This study highlights the need for improved early diagnosis methods and targeted treatments.
Researchers at MD Anderson Cancer Center identified a key signaling pathway that promotes osteosarcoma metastasis when blocked in mice. The study found significant decreases in lung metastases by targeting the Notch pathway and Hes1 gene.
Routine prostate cancer screening significantly reduces the risk of metastatic disease within 10 years after treatment. Men diagnosed post-screening had a lower risk of spreading cancer compared to those treated prior to widespread screening.
A large study found that men with localized prostate cancer who take aspirin with radiation therapy or surgery have a lower risk of dying from the disease. The use of anticoagulants reduced the risk of death by 6 percentage points, from 10% to 4%, at 10 years.
Researchers at Penn State College of Medicine have identified a potential new treatment approach targeting the protein c-Met in patients with metastatic liver cancer. By analyzing data from 1,051 patients and six published manuscripts, they found that c-Met activation is strongly associated with poor prognosis and aggressive features. ...
Researchers at UT MD Anderson Cancer Center found that TAp63, a tumor-suppressing protein, blocks cancer spread by activating Dicer and miR-130b. This discovery has far-reaching implications for understanding cancer development and metastasis.
A Phase-II trial investigating pazopanib for relapsed/refractory urothelial cancer has generated promising results, with four patients experiencing tumor shrinkage and twelve seeing their metastases die due to 'necrotic evolution'. Researchers are eager to translate this activity into a survival advantage.
Researchers reported that adding cetuximab to a three-drug chemotherapy regimen for first-line treatment of metastatic colorectal cancer did not improve response rates, progression-free survival, or overall survival. The NORDIC VII study included 566 patients and found no statistically significant differences between the treatment groups.
Researchers have found that cancer cells are accompanied by growth-enabling stromal cells when they travel to new sites in the body. This discovery challenges current understanding of metastasis and has implications for effective treatments.
A new meta-analysis shows that continuing chemotherapy after bringing cancer under control can increase survival time and reduce disease progression in metastatic breast cancer patients. The analysis found a 34% reduction in disease progression and a 9% reduction in death rates for patients who received longer chemotherapy durations.
A new melanoma treatment has shown a robust activity in shrinking brain metastases in patients with advanced disease. The drug, GSK2118436, targets the BRAF protein mutation common in human melanomas and has been found to control and reduce brain tumor size in nearly all patients.
The final phase-II results show that iniparib plus chemotherapy significantly improves overall survival from 7.7 to 12.3 months, offering a promising new treatment option for metastatic triple-negative breast cancer patients. Over half of patients experience clinical benefit, and there is little increase in adverse events.
A new type of cancer treatment has shown encouraging activity as a first-line therapy in HER2-positive metastatic disease. The study demonstrated that T-DM1 has good anti-tumor activity and much lower toxicity compared to the older standard.
The $1.5 million grant will fund Ben Major's work to identify functional human genes contributing to specific cellular processes, such as cancer growth and migration. The goal is to develop a low-cost approach to determine gene function in the human genome.
A recent clinical study has shown that patient-specific vaccines can sometimes induce durable complete regression of progressing soft-tissue melanoma metastases. The vaccine was found to be effective in one particular patient who remained in complete remission for over two years, more than four years after her initial diagnosis.
Researchers have identified LIMK as a crucial regulator of actin cytoskeleton dynamics in cancer metastasis. Inhibiting LIMK function blocks collective invasion of tumor cells, preventing metastasis in breast and squamous carcinoma cells.
Research found that chronic stress increases cancer spread by 30-fold in stressed mice compared to unstressed controls. Stress alters the biology of immune cells, promoting metastasis to distant organs. Beta blockers blocked this effect, suggesting potential prevention strategies.
CD82 and CD9 proteins are found to suppress tumor metastasis by releasing beta-catenin in exosomes, thereby inhibiting Wnt signaling. This mechanism may be compromised in certain cancers, where Wnt signaling is hyperactive.
A study by Heike Allgayer's team found that micro-RNA miR-200c inhibits the motility and invasive capacity of non-small cell lung cancer cells. Higher miR-200c levels were associated with increased tissue-anchoring molecules and lower metastasis rates.
Researchers have developed a new drug that targets peripheral CB1 cannabinoid receptors to improve cardiometabolic risk in mouse models of obesity. The drug inhibits the same protein as rimonabant, but without neurological side effects. This approach may reduce health risks associated with obesity and type 2 diabetes.
Researchers from A*STAR made three groundbreaking discoveries in fight against cancer: a mechanism to prevent metastasis, biomarkers for breast cancer, and improved detection of cervical cancer. Their work sheds light on key areas of cancer research, offering new strategies to combat this devastating disease.
A recent study uses genomic analysis to understand complex cellular signals driving lung cancer's deadly spread. The research identifies specific molecules linked to non-small cell lung cancer's (NSCLC) invasive and metastatic processes, providing a basis for effective therapies.
UAB researchers are investigating the role of inactivated DNA left behind after breast-cancer treatment. They aim to understand how this altered DNA activates cancer's deadly spread, a process called metastasis. The study could lead to improved prevention and treatment for millions of cancer patients.
A phase III clinical trial found that ipilimumab, a monoclonal antibody, significantly extended the lives of patients with metastatic melanoma. The therapy showed a 67% increase in survival time compared to those receiving gp100 alone, demonstrating its promise as an alternative treatment for cancer patients.
Researchers found that cancer cells lacking COMMD1 are more invasive and likely to metastasize, suggesting a possible drug target. Enhanced COMMD1 levels in mouse melanoma cells reduced metastatic lung tumors.
Only 5% of cancer research funds are spent on investigating metastases, yet it kills 90% of all cancer patients. The European CanCer Organisation highlights this discrepancy in funding and calls for increased emphasis on tackling metastases.
A new Mayo Clinic study found that complete removal of all tumors that spread can significantly improve prognosis for kidney cancer patients. Patients who underwent complete tumor removal had an average cancer-specific survival rate of 5 years, compared to just 1 year for those without metastatic tumors removed.
Scientists identified a novel enzyme, PEAK1, that regulates cell proliferation, shape and migration. The discovery may provide a new target for future anti-cancer therapies.
Researchers at Mayo Clinic have found a new aggressive treatment approach for anaplastic thyroid carcinoma to be highly effective, resulting in 70% one-year survival rate. The treatment combines surgery, intensity modulated radiation therapy, and chemotherapy, and is being tested in a nationwide clinical trial.
A recent study by S. Eggener et al. discusses the significance and impact of focal therapy for low-risk prostate cancer patients, highlighting its potential as an alternative to whole-gland treatment. The study reviews patient selection criteria, diagnostic imaging, biopsy schemes, and treatment modalities available for focal therapy.
Researchers at Beth Israel Deaconess Medical Center have identified palladin as a critical regulator of cell motility and migration in breast cancer. By inhibiting these processes, palladin helps suppress breast cancer invasion and metastasis.
Researchers found that PDE5 inhibitors increase blood-brain barrier permeability to Herceptin, boosting effectiveness against lung and breast cancer brain metastases. The combination of vardenafil plus Herceptin improved survival by 20% in mouse models.
A recent study presented at the ARRS Annual Meeting found that whole body MRI is highly accurate in detecting breast cancer metastases. The test identified bone metastases in 47 out of 99 patients with known breast cancer, while a chest X-ray only detected them in 24 patients.
A new study found that the number of circulating tumor cells in a patient's blood directly correlates with their survival time in metastatic breast cancer. The research suggests that monitoring these cells could improve personalized therapy for patients.
Researchers found that flaxseed-enriched diets decreased late-stage ovarian tumor severity and increased survival rates in hens. The study also showed improved weight control and reduced metastatic spread in hens fed the flaxseed diet, suggesting potential benefits for human ovarian cancer treatment.
Researchers at the University of Kentucky Markey Cancer Center have discovered a key molecular mechanism behind breast tumor cell spread. The finding focuses on Snail's interaction with LSD1 enzyme, which regulates DNA structure and shuts down E-cadherin gene expression, leading to metastasis.
Researchers found that lung cancer patients whose tumors over-express the cell surface molecule CXCR4 have significantly worse clinical outcomes and shorter overall survival times. This suggests that CXCR4 could be a promising new target for personalized cancer therapy.
Researchers at Georgetown Lombardi Comprehensive Center have identified molecular markers on breast tumors that can predict which cancers will metastasize to the lymph node system. These markers, found in both breast cancer cells and sentinel lymph nodes removed from patients, may help reduce false negative rates in sentinel node biopsy.
Researchers at Stanford University School of Medicine have identified a new genetic marker, called HOTAIR, that is significantly more prevalent in aggressive breast cancer cases. High levels of HOTAIR expression are associated with increased risk of metastasis and poorer survival rates for women with breast cancer.
An international team of researchers has discovered a four-protein complex that promotes breast cancer metastasis. The complex, involving Myc, Skp2, Miz1, and p300, is a key regulator of RhoA gene expression. Targeting this complex could lead to the development of new drugs to thwart breast cancer migration and invasion.
Researchers identify Decapentaplegic protein as key player in cell migration, found in healthy Drosophila melanogaster cells. The protein triggers cell mobility and invasion, benefiting metastasis.
Researchers found that beta-blocker treatment reduced metastasis and improved survival in breast cancer patients, with a 71% reduced risk of death compared to other groups. The study suggests that beta-blockers may slow down tumour growth and target patients at high risk of secondary cancers.
The median survival time for metastatic breast cancer patients increased steadily over 25 years, with improved outcomes for those with grade III tumours. Targeted therapies, particularly trastuzumab, have contributed to these advancements, offering new hope for patients with aggressive forms of the disease.
Patients with metastatic breast cancer expect to prolong life by at least a year over current therapies, whereas doctors consider four to six months of additional survival significant. Thorough discussion of treatment goals is essential for both groups.
A recent study found that new chemotherapy drugs for metastatic colorectal cancer can increase life expectancy by 6.8 months, but at a cost of $37,100 per patient. The cost-effectiveness of these treatments is disputed, with the study estimating a cost of $99,100 per quality-adjusted life year gained.
A study found that new chemotherapy agents for metastatic colorectal cancer improve life expectancy by 6.8 months and increase lifetime medical costs by $37,100, equating to a cost of $66,200 per year of life gained.
Researchers have made significant progress in treating spinal muscular atrophy with targeted gene therapy, improving muscle strength and coordination. Additionally, a new approach to treating Duchenne muscular dystrophy heart disease has been discovered using membrane-sealing poloxamer. Furthermore, a cancer drug has shown promise in m...
A study published in Oncogene reveals that microtentacles, extensions of plasma membrane on breast cancer cells, play a key role in metastasis. Targeting these microtentacles may provide a new way to prevent or slow the growth of secondary cancers.
Researchers at Berkeley Lab have found a novel way to influence cancer cell behavior using physical forces, which may lead to new cancer treatments. The study reveals that the EphA2/ephrin-A1 receptor-ligand complex can sense mechanical properties of its environment.
Researchers identified two biomarkers in the blood that may accurately predict the spread of colon cancer, allowing for earlier intervention and treatment. The study found these biomarkers were significantly higher in metastatic cells than primary tumor cells.
The study found that overexpressing ARD1A reduces primary tumors and metastases by blocking VEGFA expression. ARD1A's effect on tumor growth was confirmed through reduced microvessel density.
A systematic review of literature found that micrometastases in axillary lymph nodes are associated with reduced disease-free and overall survival in breast cancer patients. The study's findings suggest that even small metastatic lesions can have a significant impact on patient outcomes.
A study found that pretreatment SUVmax is a strong predictor of disease-specific survival, overall survival, and disease-free survival in head and neck squamous cell carcinoma patients. Higher SUV-LN was associated with distant metastasis, suggesting more aggressive treatment approaches may be needed.
Research associates H. pylori and EBV infections with gastric cancer development, particularly through DNA methylation and microsatellite instability alterations. CDH1 gene silencing and DAPK inverse correlation with MSI offer new insights into disease mechanisms.
A new study found that adding a contrast agent to MRI improves the accuracy of detecting lymph node metastases. The researchers concluded that incorporating contrast enhancement in malignancy criteria improves diagnostic test accuracy, and histopathologic examination should still be used as a gold standard.
The foundation provides three-year fellowships with $140,000 each to support groundbreaking projects in basic and translational cancer research. The recipients aim to pursue careers in cancer research by investigating key topics such as epigenetic alterations, protein function, and cellular behavior.
A study published in the journal Cancer found that radiofrequency ablation (RFA) significantly reduced pain from bone metastases in patients. RFA is a minimally invasive cancer treatment that uses heat to kill tumor cells, eliminating the need for strong narcotic pain management.
Researchers found TRAP-1 to be highly expressed in prostate cancer cells, inhibiting cell death, while Gamitrinib treatment killed cancer cells but not healthy ones. This suggests targeting TRAP-1 may provide a new approach for treating advanced prostate cancer.
A new study reveals that self-seeding allows circulating tumor cells to return to their primary tumor and promote local growth while increasing potential for distant metastases. The research identifies key genes responsible for this process, which may lead to targeted therapies to slow or prevent tumor progression.
Knockdown of E2F1 gene significantly reduced the invasive potential of melanoma cells without affecting proliferation rates. EGFR expression was also decreased in E2F1-silenced cells, further supporting the role of E2F1 in cancer progression.